Verastem, Inc. (NASDAQ:VSTM) CFO Sells $21,084.30 in Stock

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) CFO Daniel Calkins sold 4,110 shares of Verastem stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $5.13, for a total transaction of $21,084.30. Following the completion of the transaction, the chief financial officer now directly owns 109,945 shares in the company, valued at approximately $564,017.85. This trade represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Daniel Calkins also recently made the following trade(s):

• On Monday, June 23rd, Daniel Calkins sold 25 shares of Verastem stock. The shares were sold at an average price of $4.71, for a total value of $117.75.
• On Tuesday, May 20th, Daniel Calkins sold 11,143 shares of Verastem stock. The shares were sold at an average price of $8.13, for a total value of $90,592.59.

Verastem Stock Performance

Shares of VSTM opened at $4.15 on Friday. The company has a market capitalization of $228.04 million, a PE ratio of -1.30 and a beta of 0.85. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.50 and a quick ratio of 3.50. Verastem, Inc. has a one year low of $2.10 and a one year high of $9.10. The company's fifty day moving average price is $6.61 and its 200 day moving average price is $5.98.

Verastem (NASDAQ:VSTM - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.24). As a group, analysts expect that Verastem, Inc. will post -3.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on VSTM shares. HC Wainwright raised their price target on shares of Verastem from $10.00 to $14.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Guggenheim lifted their target price on shares of Verastem from $13.00 to $14.00 and gave the company a "buy" rating in a research note on Monday, March 24th. Royal Bank Of Canada raised shares of Verastem from an "outperform" rating to a "moderate buy" rating and dropped their price target for the stock from $16.00 to $12.00 in a research note on Wednesday. Wall Street Zen lowered Verastem from a "hold" rating to a "sell" rating in a report on Friday, April 18th. Finally, Jefferies Financial Group assumed coverage on Verastem in a research note on Thursday, April 10th. They issued a "buy" rating and a $15.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $13.38.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in VSTM. Balyasny Asset Management L.P. bought a new position in Verastem during the fourth quarter valued at about $20,400,000. Nantahala Capital Management LLC grew its holdings in shares of Verastem by 0.5% during the 4th quarter. Nantahala Capital Management LLC now owns 3,752,583 shares of the biopharmaceutical company's stock worth $19,401,000 after purchasing an additional 19,250 shares in the last quarter. AIGH Capital Management LLC acquired a new stake in shares of Verastem during the 4th quarter worth approximately $13,778,000. BVF Inc. IL increased its position in shares of Verastem by 24.6% during the fourth quarter. BVF Inc. IL now owns 2,100,468 shares of the biopharmaceutical company's stock valued at $10,859,000 after purchasing an additional 415,249 shares during the period. Finally, Octagon Capital Advisors LP acquired a new position in shares of Verastem in the first quarter valued at $10,372,000. Institutional investors and hedge funds own 88.37% of the company's stock.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.